First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses. Association between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results